IN2014CN02971A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02971A
IN2014CN02971A IN2971CHN2014A IN2014CN02971A IN 2014CN02971 A IN2014CN02971 A IN 2014CN02971A IN 2971CHN2014 A IN2971CHN2014 A IN 2971CHN2014A IN 2014CN02971 A IN2014CN02971 A IN 2014CN02971A
Authority
IN
India
Prior art keywords
formula
compound
alkyl
halo
orn
Prior art date
Application number
Other languages
English (en)
Inventor
Jo Ann Wilson
Sriram Naganathan
Matthew Pfeiffer
Neil G Andersen
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of IN2014CN02971A publication Critical patent/IN2014CN02971A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/59Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN2971CHN2014 2011-10-20 2012-10-22 IN2014CN02971A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549312P 2011-10-20 2011-10-20
PCT/US2012/061320 WO2013059788A1 (en) 2011-10-20 2012-10-22 Process for preparing quinoline derivatives

Publications (1)

Publication Number Publication Date
IN2014CN02971A true IN2014CN02971A (es) 2015-07-03

Family

ID=47146705

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2971CHN2014 IN2014CN02971A (es) 2011-10-20 2012-10-22

Country Status (24)

Country Link
US (3) US9365516B2 (es)
EP (1) EP2768796B1 (es)
JP (2) JP6208140B2 (es)
KR (1) KR102075371B1 (es)
CN (2) CN104395284A (es)
AR (1) AR088483A1 (es)
AU (2) AU2012325768B2 (es)
BR (1) BR112014009302B1 (es)
CA (1) CA2852771C (es)
DK (1) DK2768796T3 (es)
EA (1) EA031485B1 (es)
ES (1) ES2765013T3 (es)
GE (1) GEP20207110B (es)
HK (1) HK1201517A1 (es)
HU (1) HUE048023T2 (es)
IL (1) IL232139A (es)
IN (1) IN2014CN02971A (es)
MX (1) MX343288B (es)
PL (1) PL2768796T3 (es)
PT (1) PT2768796T (es)
TW (2) TWI619694B (es)
UA (1) UA116876C2 (es)
WO (1) WO2013059788A1 (es)
ZA (1) ZA201402579B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114209699A (zh) 2010-07-16 2022-03-22 埃克塞里艾克西斯公司 C-met调节剂药物组合物
EP2621481B2 (en) 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
KR20210010671A (ko) 2011-02-10 2021-01-27 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
GEP201706678B (en) 2011-05-02 2017-06-12 Exelixis Inc Method of treating cancer and bone cancer
EP3275443A1 (en) 2011-09-22 2018-01-31 Exelixis, Inc. Method for treating osteoporosis
EA031485B1 (ru) * 2011-10-20 2019-01-31 Экселиксис, Инк. Способ получения хинолиновых производных
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス, インク. 溶骨性骨転移を治療するためのmet−vegf二重調節剤
JP6389238B2 (ja) 2013-03-15 2018-09-12 エグゼリクシス, インコーポレイテッド N−(4−{[6,7−ビス(メンチルオキシ)キノリン−4−イル]オキシ}フェニル)−n’−(4−フルオロフェニル)サイクロプロペイン−1,1−ジカルボキシアミドのメタボライト
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
CN104649969B (zh) * 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
EA032757B1 (ru) 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
WO2015142928A1 (en) 2014-03-17 2015-09-24 Exelixis, Inc. Dosing of cabozantinib formulations
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
CA2956810C (en) 2014-07-31 2022-10-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
WO2016022697A1 (en) 2014-08-05 2016-02-11 Exelixis, Inc. Drug combinations to treat multiple myeloma
WO2017036405A1 (zh) * 2015-09-02 2017-03-09 陈昆锋 具有蛋白酪氨酸磷酸酶shp-1激动剂活性的化合物
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN109836382B (zh) * 2017-11-29 2021-11-05 江苏豪森药业集团有限公司 苹果酸卡博替尼及其中间体的制备方法
BR112020015201A2 (pt) 2018-01-26 2020-12-29 Exelixis, Inc. Compostos para tratamento contra distúrbios dependentes de quinase
CN112142619B (zh) * 2020-10-20 2023-01-10 浙江工业大学 一种1,1-环丙烷二羧酸酰胺类化合物及其制备方法和应用
WO2024111001A1 (en) * 2022-11-25 2024-05-30 Msn Laboratories Private Limited, R&D Center Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004275842B2 (en) 2003-09-26 2010-09-02 Exelixis Inc. c-MET modulators and methods of use
JP5368701B2 (ja) * 2004-07-02 2013-12-18 エクセリクシス、インコーポレイテッド c−Metモジュレーター及び使用方法
EP1874759A4 (en) 2005-04-06 2009-07-15 Exelixis Inc C-MET MODULATORS MODULATORS AND METHODS OF USE
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス, インコーポレイテッド Mek阻害剤の使用方法
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009136663A1 (en) * 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
TW201035017A (en) 2008-09-26 2010-10-01 Smithkline Beecham Corp Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide
WO2010056960A1 (en) * 2008-11-13 2010-05-20 Exelixis Inc. Methods of preparing quinoline derivatives
WO2010065838A1 (en) 2008-12-04 2010-06-10 Exelixis, Inc. Methods of preparing quinoline derivatives
KR20210151988A (ko) 2009-01-16 2021-12-14 엑셀리시스, 인코포레이티드 암의 치료를 위한 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
AU2010274012A1 (en) 2009-07-17 2012-02-09 Exelixis, Inc. Crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy] -quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
MX2012010506A (es) 2010-03-12 2012-10-15 Exelixis Inc Formas cristalinas hidratadas del n-[3-fluoro-4-({6-(metiloxi)-7-[ (3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluoro fenil)ciclopropano-1,1-dicarboxamida.
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
CN114209699A (zh) 2010-07-16 2022-03-22 埃克塞里艾克西斯公司 C-met调节剂药物组合物
WO2012009723A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
AU2011307309A1 (en) 2010-09-27 2013-05-02 Exelixis, Inc. Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
CA2812753A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
EP2621481B2 (en) 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
US20130252956A1 (en) 2010-11-22 2013-09-26 Howard Kallender Methods of treating cancer
KR20210010671A (ko) 2011-02-10 2021-01-27 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
GEP201706678B (en) 2011-05-02 2017-06-12 Exelixis Inc Method of treating cancer and bone cancer
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
EP3275443A1 (en) 2011-09-22 2018-01-31 Exelixis, Inc. Method for treating osteoporosis
EA031485B1 (ru) 2011-10-20 2019-01-31 Экселиксис, Инк. Способ получения хинолиновых производных
EP2776033A1 (en) 2011-11-08 2014-09-17 Exelixis, Inc. Dual inhibitor of met and vegf for treating cancer
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス, インク. 溶骨性骨転移を治療するためのmet−vegf二重調節剤
CN114129566A (zh) 2012-09-07 2022-03-04 埃克塞里艾克西斯公司 用于治疗肺腺癌的met、vegfr和ret的抑制剂

Also Published As

Publication number Publication date
JP6208140B2 (ja) 2017-10-04
PT2768796T (pt) 2020-02-21
MX343288B (es) 2016-11-01
KR102075371B1 (ko) 2020-02-10
MX2014004583A (es) 2014-10-06
US9365516B2 (en) 2016-06-14
KR20140088874A (ko) 2014-07-11
UA116876C2 (uk) 2018-05-25
AU2012325768B2 (en) 2017-08-10
GEAP201913471A (en) 2019-10-25
PL2768796T3 (pl) 2020-05-18
AU2012325768A1 (en) 2014-05-22
IL232139A0 (en) 2014-05-28
JP2014530880A (ja) 2014-11-20
CN104395284A (zh) 2015-03-04
EP2768796A1 (en) 2014-08-27
TWI642650B (zh) 2018-12-01
GEP20207110B (en) 2020-05-25
DK2768796T3 (da) 2020-02-24
ES2765013T3 (es) 2020-06-05
EA201490831A1 (ru) 2014-09-30
BR112014009302B1 (pt) 2020-04-28
ZA201402579B (en) 2015-03-25
CA2852771A1 (en) 2013-04-25
US20160229805A1 (en) 2016-08-11
HK1201517A1 (en) 2015-09-04
AR088483A1 (es) 2014-06-11
TWI619694B (zh) 2018-04-01
US20180230100A1 (en) 2018-08-16
AU2017254982A1 (en) 2017-11-23
US9969692B2 (en) 2018-05-15
HUE048023T2 (hu) 2020-05-28
JP2017222648A (ja) 2017-12-21
TW201731812A (zh) 2017-09-16
BR112014009302A2 (pt) 2017-05-23
WO2013059788A1 (en) 2013-04-25
NZ723880A (en) 2018-03-23
TW201321342A (zh) 2013-06-01
CA2852771C (en) 2019-11-26
EA031485B1 (ru) 2019-01-31
NZ624328A (en) 2016-10-28
US20140256938A1 (en) 2014-09-11
CN110511158A (zh) 2019-11-29
EP2768796B1 (en) 2019-11-20
IL232139A (en) 2017-11-30

Similar Documents

Publication Publication Date Title
IN2014CN02971A (es)
MX352470B (es) Disales de acido malonico y metodo para preparar dihaluros de malonilo.
AU2012248061C1 (en) Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
MX2018007106A (es) Metodo de produccion de un derivado de amida aromatica.
IN2014DN00144A (es)
NZ601805A (en) Method for preparing tetrazole methanesulfonic acid salts, and novel compound used in same
IN2012DN01104A (es)
UA111868C2 (uk) Спосіб одержання естерів (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)-оцтової кислоти
IN2014MN00976A (es)
IN2014MN00850A (es)
IN2014CN02346A (es)
MX337997B (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
IN2012DN00361A (es)
MX2013008595A (es) Procedimiento mejorado para la preparacion de 2,2-difluoroetilamina.
JO3200B1 (ar) طريقة ونواتج وسيطة لتحضير أجوميلاتين
IN2014CN04123A (es)
EA201400563A1 (ru) Способ получения хинолинкарбоновой кислоты
BR112013018809A8 (pt) Processo para produção de derivados de ácido amidocarboxílico aromático
MX345768B (es) Procedimiento para la preparación de 2,2-dufluoroetilamina partiendo de un compuesto de bencilamina.
NZ709587A (en) Method for preparing cyclopropane derivatives
RU2012114930A (ru) Способ получения ароматических аминосульфокислот
MY161361A (en) Substituted phenyl compounds
GEP20156369B (en) New process for synthesis of ivabradine and addition salts therewith pharmaceutically acceptable acid
IN2014DN10440A (es)
MX2014008995A (es) Compuesto novedoso de ester de acido acetico o una sal del mismo.